×
About 175 results

ALLMedicine™ Fibrolamellar Carcinoma Center

Research & Reviews  58 results

Pediatric HCC: Histologic subtypes demonstrate distinct clinical patterns
https://www.mdedge.com/gihepnews/article/255714/hepatocellular-carcinoma/pediatric-hcc-histologic-subtypes-demonstrate

Jun 23rd, 2022 - Key clinical point: The pediatric hepatocellular carcinoma (HCC) subtypes fibrolamellar carcinoma (FLC) and conventional HCC (cHCC) can be considered nonequivalent entities because they show different anatomic patterns and outcomes together with t.

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
https://clinicaltrials.gov/ct2/show/NCT03860272

Jun 23rd, 2022 - This Phase 1 study will enroll up to approximately 195 evaluable adult participants with refractory cancer (solid tumors) regardless of diagnosis. The study will consist of a 3+3 dose escalation. Different dose levels of botensilimab, both monothe...

Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pe...
https://doi.org/10.1002/cncr.34256
Cancer Short SS, Kastenberg ZJ et. al.

May 14th, 2022 - Hepatocellular carcinoma (HCC) is a rare cancer in children, with various histologic subtypes and a paucity of data to guide clinical management and predict prognosis. A multi-institutional review of children with hepatocellular neoplasms was perf...

Successful liver transplantation of recurrent fibrolamellar carcinoma following clinica...
https://doi.org/10.1159/000524872
Oncology Research and Treatment; Kang S, Magliocca J et. al.

May 11th, 2022 - Fibrolamellar carcinoma (FLC) is a rare liver cancer that predominantly affects younger patients without a history of liver disease. Surgical resection is the cornerstone of therapy and represents the best potentially curative treatment option. Mo...

A framework for fibrolamellar carcinoma research and clinical trials.
https://doi.org/10.1038/s41575-022-00580-3 10.1002/1097-0142(19800915)46:6<1448::AID-CNCR2820460626>3.0.CO;2-J 10.1002/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S 10.1002/1097-0142(19820815)50:4<702::AID-CNCR2820500414>3.0.CO;2-F 10.1016/j.currproblcancer.2021.100770 10.1016/j.jamcollsurg.2012.08.001 10.1053/j.semdp.2016.12.010 10.3322/caac.21585 10.1097/PPO.0000000000000343 10.1177/2050640613501507 10.1007/s10620-020-06135-3 10.6064/2012/743790 10.1016/j.path.2018.02.006 10.2147/JHC.S215235 10.1186/s12957-020-01855-2 10.1038/srep44653 10.1002/cncr.21703 10.1016/j.jamcollsurg.2013.10.011 10.1002/jso.24515 10.1542/peds.82.3.379 10.1159/000499581 10.21037/jgo.2019.01.28 10.1002/pbc.27392 10.1055/s-0037-1621710 10.1002/pbc.25970 10.1038/modpathol.2017.103 10.1038/modpathol.2010.207 10.1038/modpathol.2010.105 10.1002/hep.27018 10.1053/j.gastro.2014.12.028 10.1093/hmg/ddu418 10.1073/pnas.1424894112 10.1126/science.1249484 10.1038/ncomms9070 10.1093/annonc/mdw135 10.1371/journal.pone.0176562 10.18632/oncotarget.2712 10.1038/modpathol.2015.4 10.1053/j.gastro.2019.10.028 10.1038/s41379-019-0398-2 10.1007/s00018-006-6192-6 10.1001/jama.1989.03430130091040 10.1038/nrm3432 10.1016/j.gene.2015.11.052 10.1055/s-0031-1272835 10.1002/cncr.32960 10.1158/0008-5472.CAN-06-3114 10.1016/j.celrep.2020.03.073 10.1002/cncr.27520 10.6061/clinics/2015(03)10 10.1016/j.jhep.2019.06.001 10.1016/j.jhep.2019.12.006 10.1002/jcb.28651 10.1053/j.gastro.2017.09.008 10.1073/pnas.1716483114 10.21037/atm.2018.06.14 10.1155/2017/6456257 10.1021/cb900038e 10.18632/oncotarget.27149 10.1073/pnas.1906036116 10.1038/pr.2016.36 10.1055/a-0753-4943 10.1002/hep.29719 10.1073/pnas.1424206112 10.1038/s41598-017-18956-w 10.1016/j.str.2019.03.001 10.1371/journal.pbio.3001018 10.1038/s42003-021-01819-6 10.1126/science.aaj1669 10.1146/annurev-pharmtox-011112-140204 10.3389/fendo.2018.00538 10.7554/eLife.44187 10.1126/science.aaf4382 10.1016/j.tcb.2018.02.004 10.1016/j.cell.2020.07.043 10.1016/j.humpath.2006.07.019 10.1158/1078-0432.CCR-04-0941 10.1038/modpathol.2014.78 10.1111/his.12799 10.1002/hep.22695 10.1200/jco.2013.31.4_suppl.232 10.21037/jgo.2019.01.35 10.1371/journal.pone.0089388 10.18632/oncotarget.23325 10.1016/j.jcmgh.2019.01.008 10.1016/j.ccell.2016.03.010 10.1016/j.tcb.2017.11.008 10.1038/s41568-021-00353-1 10.1016/j.cell.2013.09.053 10.1101/2021/08.11.455931 10.1242/dmm.042564 10.1158/2159-8290.CD-20-0872 10.1002/hep.24590 10.1038/nrgastro.2012.23 10.1111/iep.12364 10.1007/s40265-017-0759-4 10.1021/acs.jnatprod.8b00247 10.3389/fphar.2020.597520 10.3390/cancers11030276 10.1158/1078-0432.CCR-19-0302 10.1038/nrclinonc.2016.58 10.2217/imt-2017-0029 10.1016/j.intimp.2018.06.001 10.1158/1535-7163.MCT-17-0386 10.1056/NEJMc1713444 10.1158/1535-7163.MCT-20-0161 10.1016/j.annonc.2020.07.002 10.1016/S1470-2045(20)30445-9 10.1158/2326-6066.CIR-18-0499 10.1159/000497464 10.1016/j.ccell.2018.03.005 10.1001/jamaoncol.2020.4564 10.1038/nrc.2017.74 10.1186/s13073-017-0468-3 10.1126/scitranslmed.aat8549 10.1097/SLA.0b013e31824856f5 10.1097/SLA.0b013e318265fd3e 10.1055/s-0034-1396420 10.1159/000354698 10.1002/cncr.11292 10.1158/0008-5472.CAN-06-1377 10.1517/14656566.2010.496453 10.1007/s11523-017-0484-7 10.1002/onco.13566 10.1200/JCO.2021.39.15_suppl.e16161 10.1038/nature11083 10.1097/MPH.0b013e3182011676 10.1634/theoncologist.2020-0367 10.3389/fonc.2015.00278 10.1158/1535-7163.MCT-10-0574 10.1634/theoncologist.2020-0093 10.1016/j.humpath.2005.12.009 10.1007/s12253-012-9558-0 10.1517/13543780903305428 10.1200/JCO.2021.39.3_suppl.310 10.1038/s41467-018-06916-5 10.1016/j.gde.2019.02.007 10.1038/s41586-019-1186-3 10.15252/msb.20209757 10.1007/s11864-006-0045-2 10.1038/nm.4389 10.21037/jgo.2017.09.10 10.1159/000513358 10.1126/science.aan5931 10.1016/S2352-3026(16)00007-7 10.1016/S1470-2045(15)00388-5 10.1038/s41591-019-0749-z 10.1016/S1470-2045(15)00485-4 10.1016/S1470-2045(15)00386-1 10.1056/NEJMsb1609216 10.1016/j.ejso.2018.02.015 10.1038/nchembio.1858 10.1016/j.chembiol.2017.08.002 10.1016/j.cell.2017.06.010 10.7554/eLife.57116 10.1371/journal.pone.0177802 10.1038/nbt.3374 10.1002/pbc.26919
Nature Reviews. Gastroenterology & Hepatology; Dinh TA, Utria AF et. al.

Feb 23rd, 2022 - Fibrolamellar carcinoma (FLC), a rare, lethal hepatic cancer, occurs primarily in adolescents and young adults. Unlike hepatocellular carcinoma, FLC has no known association with viral, metabolic or chemical agents that cause cirrhosis. Currently,...

see more →

Clinicaltrials.gov  4 results

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
https://clinicaltrials.gov/ct2/show/NCT03860272

Jun 23rd, 2022 - This Phase 1 study will enroll up to approximately 195 evaluable adult participants with refractory cancer (solid tumors) regardless of diagnosis. The study will consist of a 3+3 dose escalation. Different dose levels of botensilimab, both monothe...

A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02234986

Sep 6th, 2018 - Primary Objective: • To determine the 6-month progression free survival (PFS6) rate when patients with advanced fibrolamellar carcinoma (FLC) are treated with daily oral ENMD 2076 Secondary Objectives: To evaluate the overall response rate using R...

Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma
https://clinicaltrials.gov/ct2/show/NCT01215565

Mar 13th, 2014 - Fibrolamellar hepatocellular carcinoma is variant rare of hepatocellular carcinoma witch distinct clinical, histological and prognostic features from conventional hepatocellular carcinoma. This entity typically occurs in young adults with no under...

Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer
https://clinicaltrials.gov/ct2/show/NCT00899002

Apr 10th, 2013 - OBJECTIVES: To characterize, at a molecular level, archived samples of tissue from young patients with fibrolamellar carcinoma and hepatocellular carcinoma in non-cirrhotic livers matched for age and sex. To perform genomic analysis on these tissu...

see more →

News  8 results

Pediatric HCC: Histologic subtypes demonstrate distinct clinical patterns
https://www.mdedge.com/gihepnews/article/255714/hepatocellular-carcinoma/pediatric-hcc-histologic-subtypes-demonstrate

Jun 23rd, 2022 - Key clinical point: The pediatric hepatocellular carcinoma (HCC) subtypes fibrolamellar carcinoma (FLC) and conventional HCC (cHCC) can be considered nonequivalent entities because they show different anatomic patterns and outcomes together with t.

Abou-Alfa Highlights HCC Advances, Unmet Needs in Other GI Cancers
https://www.onclive.com/view/aboualfa-highlights-hcc-advances-unmet-needs-in-other-gi-cancers

Oct 6th, 2021 - Ghassan Abou-Alfa, MD While the hepatocellular carcinoma (HCC) field shifted in 2018 with the addition of newly available treatment options, more pivotal research is on the way, said Ghassan K. Abou-Alfa, MD. For a 10-year span, there was only 1...

Frontline Cabozantinib Plus Atezolizumab Significantly Improves PFS in Advanced HCC
https://www.onclive.com/view/frontline-cabozantinib-plus-atezolizumab-significantly-improves-pfs-in-advanced-hcc

Jun 28th, 2021 - The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) was found to significantly improve progression-free survival (PFS) compared with sorafenib (Nexavar) when used in the first-line treatment of patients with advanced hepatocel...

Cabozantinib Approved in Japan for Advanced Hepatocellular Carcinoma
https://www.onclive.com/view/cabozantinib-approved-in-japan-for-advanced-hepatocellular-carcinoma

Nov 30th, 2020 - The Japanese Ministry of Health, Labor, and Welfare has approved cabozantinib (Cabometyx) for the treatment of patients with unresectable hepatocellular carcinoma (HCC) that has progressed on prior systemic therapy.1 The approval is based on resu...

MicroRNA-375 may be key to fibrolamellar carcinoma
https://www.mdedge.com/gihepnews/article/198920/liver-disease/microrna-375-may-be-key-fibrolamellar-carcinoma?channel=69
Will Pass, MDedge News

Apr 15th, 2019 - Up-regulation of microRNA-375 may be a future therapeutic strategy for patients with fibrolamellar carcinoma (FLC), according to investigators. Analysis of primary FLC tumors showed that microRNA-375 was the most abnormal microRNA, down-regulated.

see more →